BCBS Alabama · Weight Loss

BCBS Alabama coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

Age >= 18 years
BMI >= 30 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Adult overweight with comorbidity

All of:

Age >= 18 years
BMI >= 27 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Plus any one of:

Hypertension
Type 2 diabetes
Dyslipidemia
OSA
CVD
MASH
other weight-related comorbidity

Documentation to bring

Baseline BMI documentation meeting threshold (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 23 kg/m2 for qualifying Asian ethnicities)
Documentation of qualifying weight-related comorbidity if BMI 27–29.9 kg/m2
Documentation of reduced-calorie diet and increased physical activity as adjunct

Approval and renewal

To renew, the plan looks for at least 5% weight loss from the starting weight, At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation per guideline-based efficacy assessment standard cited in document, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Coadministration with other tirzepatide-containing products not recommended
Coadministration with any GLP-1 receptor agonist not recommended
Pregnancy

Policy note: Covers both Zepbound subcutaneous injection solution vial and Zepbound KwikPen formulations. Adult-only FDA indication for weight loss (no pediatric indication for tirzepatide at time of policy). The 5% weight loss threshold at 12 weeks is cited from guidelines as the efficacy assessment standard applicable to all weight management agents.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

Age >= 18 years
BMI >= 30 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Adult overweight with comorbidity

All of:

Age >= 18 years
BMI >= 27 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, East Asian adults)

Plus any one of:

Hypertension
Type 2 diabetes
Dyslipidemia
OSA
CVD
MASH
other weight-related comorbidity

Documentation to bring

Baseline BMI documentation meeting threshold (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 23 kg/m2 for qualifying Asian ethnicities)
Documentation of qualifying weight-related comorbidity if BMI 27–29.9 kg/m2
Documentation of reduced-calorie diet and increased physical activity as adjunct

Approval and renewal

To renew, the plan looks for at least 5% weight loss from the starting weight, At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation per guideline-based efficacy assessment standard cited in document, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Coadministration with other tirzepatide-containing products not recommended
Coadministration with any GLP-1 receptor agonist not recommended
Pregnancy

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf

All Zepbound policies under BCBS Alabama · Check your card